GlassScriptPhysician profile
William Huang
NPI 1821177569
$1,652.65
in general payments reported to CMS, 2019-2025
29 companies · $79.95 in 2025
The $79.95 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2022: $375 · 2023: $618 · 2024: $456 · 2025: $79.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131 · Education: $23.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,131.07 |
| Education | $23.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $277.52 | 2022-2025 | Imfinzi, Calquence, Lynparza |
| Merck Sharp & Dohme LLC | $207.83 | 2022-2024 | Keytruda, Welireg, Lenvima |
| Genzyme Corporation | $178.23 | 2019-2023 | |
| Celgene Corporation | $123.60 | 2023-2024 | Reblozyl, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $102.81 | 2022-2024 | Ninlaro |
| Taiho Oncology, INC. | $64.92 | 2023 | |
| Abbvie INC. | $63.59 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $62.36 | 2022-2023 | Opdualag, Opdivo |
| Array Biopharma INC | $53.08 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Sumitomo Pharma America, INC. | $46.12 | 2023 | Orgovyx |
| Exelixis INC. | $41.76 | 2023 | Cabometyx |
| Incyte Corporation | $38.57 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $32.16 | 2022-2024 | Onivyde |
| Deciphera Pharmaceuticals INC. | $31.31 | 2022-2024 | Qinlock |
| Jazz Pharmaceuticals INC. | $31.12 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $27.51 | 2022 | |
| Dendreon Pharmaceuticals LLC | $27.19 | 2022 | |
| Daiichi Sankyo INC. | $26.85 | 2025 | Enhertu |
| Mirati Therapeutics, INC. | $26.46 | 2023 | Krazati |
| Springworks Therapeutics, INC. | $25.55 | 2024 | Ogsiveo |
| Novartis Pharmaceuticals Corporation | $24.89 | 2023 | |
| Astellas Pharma US INC | $23.54 | 2023 | Xtandi |
| Emd Serono, INC. | $20.62 | 2022 | |
| Amgen INC. | $19.92 | 2022 | |
| Myovant Sciences INC. | $18.99 | 2022 | |
| Aveo Pharmaceuticals, INC. | $15.12 | 2022 | |
| Polynovo North America LLC | $14.65 | 2024 | Novosorb Btm |
| Genmab U.S., INC. | $13.38 | 2023 | Epkinly |
| Janssen Biotech, INC. | $13.00 | 2023 | Rybrevant, Erleada |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.